UROTHELIAL CARCINOMA

This study tests whether giving the drug enfortumab vedotin less often can still control advanced bladder cancer while reducing side effects. About 60 adults with metastatic or locally advanced urothelial carcinoma will receive the drug alone or with pembrolizumab. The goal is to…

This study tests whether combining two immunotherapy drugs (BGB-A445 and tislelizumab) can shrink tumors in people with advanced bladder, kidney, or skin cancer that has spread. About 113 participants who have already tried at least one prior treatment will receive the drug combo…

This study tests whether a virus-based treatment called cretostimogene grenadenorepvec can prevent intermediate-risk bladder cancer from returning after surgery. About 367 participants will either receive the treatment or be monitored. The goal is to see if the therapy extends th…

This study tests whether a combination of two drugs (disitamab vedotin and pembrolizumab) works better than standard chemotherapy for people with advanced bladder cancer that has spread. About 412 participants will be randomly assigned to receive either the new combo or chemo. Th…

This early-phase trial tests whether immune cells taken from a patient's own bladder tumor can be safely given back to fight high-grade bladder cancer that hasn't spread into muscle. The study involves 9 people who have already received standard BCG treatment. The main goal is to…

This early-phase study tests whether a new immune cell therapy called CIML NK cells, combined with a low dose of IL-2, is safe and feasible for people with advanced kidney or bladder cancers. The therapy uses a patient's own immune cells that are trained in a lab to better recogn…

This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy (gemcitabine and cisplatin) is safe and effective for people with advanced bladder cancer. About 54 adults with metastatic or muscle-invasive bladder cancer will receive the combination. …

This study tests a new drug called SKB264 in people with advanced solid tumors (like lung, breast, or ovarian cancer) that have not responded to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 1,410 participants will receive t…

This study tests a drug called erdafitinib, which targets specific gene changes in cancer cells, for people with advanced bladder cancer that has spread. It involves about 125 participants and looks at safety and how well the tumor shrinks when erdafitinib is used alone or with o…

This early-stage study tests the safety of combining two drugs, avelumab and AVB-S6-500, in people with advanced urothelial carcinoma (bladder cancer) that has spread or cannot be removed by surgery. The 19 participants have already tried at least one standard chemotherapy. The g…

This study tests an experimental drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the safest dose and see if the drug can shrink tumors. About 310 adults whose cancer has not respon…

This trial tests a new antibody drug called acasunlimab (GEN1046) in people with advanced solid tumors that have stopped responding to standard treatments. The study has two parts: first, to find safe doses, and second, to see how well the drug works alone or combined with other …

This study aimed to test two treatments for muscle-invasive bladder cancer in patients who cannot receive the standard chemotherapy drug cisplatin. The treatments were erdafitinib (a targeted pill) alone or combined with atezolizumab (an immunotherapy). The goal was to see if the…

This study tests whether adding urelumab to nivolumab (both immunotherapy drugs) before bladder removal surgery improves the immune response against muscle-invasive bladder cancer. It includes 15 patients who either cannot receive standard chemotherapy due to health reasons or ch…

This study tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy helps people with advanced bladder cancer live longer. About 420 adults who have not had prior treatment for their advanced cancer will receive either tislelizumab or a placebo, along wit…

This study tests whether the immunotherapy drug pembrolizumab can shrink muscle-invasive bladder cancer enough to allow some patients to keep their bladder. About 46 adults with localized cancer will receive pembrolizumab, then be rechecked. If the cancer is gone or nearly gone, …

This early-phase study tests a drug called veliparib combined with two standard chemotherapy drugs (carboplatin and paclitaxel) in people with advanced solid tumors who also have liver or kidney dysfunction. The main goals are to find the safest dose and understand how the body p…

This study looks at adding the immunotherapy drug atezolizumab to standard chemotherapy for people with advanced bladder cancer that has spread. Researchers want to see if giving the drugs in a different order changes how well they work. About 32 adults with this type of cancer w…

This early-phase trial studies whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can help people with rare, aggressive small cell or neuroendocrine cancers of the bladder or prostate. About 15 participants with cancer that has spread will receive the co…

This study is for people with advanced solid tumors (like lung, bladder, or skin cancer) whose disease has progressed after standard immunotherapy. It tests a new drug combination designed to boost the immune system to fight cancer. About 40 participants will receive the experime…

This study tests an experimental drug called INBRX-106, given alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced solid tumors (like lung, head and neck, melanoma, stomach, kidney, or bladder cancer) that have stopped responding to standard treatment…

This study tests a new drug, UGN-103, placed directly into the bladder to treat a common type of bladder cancer that hasn't spread deep into the bladder wall. About 99 people with low-grade, intermediate-risk bladder cancer will receive the treatment. The main goal is to see if t…

This study was designed to test a combination of three drugs (N-803, pembrolizumab, and enfortumab vedotin) in people with advanced bladder cancer who had not received prior treatment. The goal was to see if the combination was safe and helped control the cancer. However, the tri…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy helps people with bladder cancer that has spread to nearby lymph nodes. About 60 participants will receive either chemo alone or chemo plus durvalumab, followed by maintenance durvalumab fo…

This study tests a combination of three drugs (pemetrexed, etrumadenant, and zimberelimab) in 10 adults with advanced bladder cancer that has a specific genetic change called MTAP deficiency. All participants had prior immunotherapy. The goal is to see if the combo shrinks tumors…

This early-stage trial tests an experimental drug called IMP321, which aims to boost the immune system's ability to fight cancer. It is given alongside standard treatments like chemotherapy or immunotherapy to people with advanced solid tumors that have spread. The main goal is t…

This study collects blood, urine, and tissue samples from 589 people to find new DNA markers that could help detect kidney and urinary tract cancers earlier. Researchers are looking for specific changes in DNA methylation that are unique to these cancers. The goal is to develop a…

This study compares two CT scan methods (single-bolus vs. split-bolus) to see which better detects urinary tract cancers. About 352 adults aged 40+ with blood in urine or a history of urothelial cancer will be randomly assigned to one of the two scans. The goal is to find out if …

This study follows over 2,700 patients with bladder, lung, or liver cancer who received the drug atezolizumab as part of their normal care. Researchers are tracking how long patients live and how well the drug controls the cancer outside of strict clinical trial settings. The goa…

This early-phase study tests a new imaging agent called 68Ga-FAPI-46, which targets cells around tumors. About 26 adults with various cancers will receive the tracer and then have a PET/CT scan. The goal is to see where the tracer goes in the body and compare it to standard imagi…

This early-phase study tests a special PET scan agent (18F-fluciclovine) to see if it can more accurately show how far muscle-invasive bladder cancer has spread compared to standard CT or MRI scans. Sixteen adults with bladder cancer scheduled for bladder removal surgery will rec…

This study looks back at medical records of 360 Japanese patients with advanced bladder cancer who received avelumab as a maintenance therapy after initial chemotherapy. The goal is to understand patient characteristics, treatment patterns, and outcomes like survival and tumor re…